Physician profile
Anil Ramesh
NPI 1518122324
$6,488.07
in general payments reported to CMS, 2019-2025
25 companies · $1,191 in 2025
The $1,191 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $19.57 · 2021: $267 · 2022: $1,166 · 2023: $1,802 · 2024: $2,042 · 2025: $1,191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,973 · Education: $61.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,973.45 |
| Education | $61.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $948.73 | 2021-2025 | Farxiga, Airsupra, Lokelma |
| Otsuka America Pharmaceutical, INC. | $518.72 | 2021-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $515.85 | 2022-2025 | |
| Travere Therapeutics, INC. | $471.31 | 2022-2025 | |
| Vifor Pharma, INC. | $441.28 | 2020-2023 | Veltassa, Korsuva |
| Amgen INC. | $437.68 | 2021-2025 | Tavneos, Krystexxa, Parsabiv |
| Ardelyx, INC. | $374.11 | 2024-2025 | Ibsrela, Xphozah 30 Mg |
| Calliditas Therapeutics US INC. | $373.67 | 2023-2025 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $369.51 | 2022-2024 | Rayaldee |
| Ani Pharmaceuticals, INC. | $356.55 | 2022-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $296.94 | 2022-2024 | Acthar, Terlivaz |
| Alexion Pharmaceuticals, INC. | $239.67 | 2022-2025 | Ultomiris |
| Mylan Specialty L.P. | $204.96 | 2021-2023 | Yupelri |
| Fresenius USA Marketing, INC. | $157.47 | 2023-2024 | Velphoro |
| Lilly USA, LLC | $140.35 | 2024-2025 | Jardiance |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $127.28 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $125.16 | 2022 | |
| Novartis Pharmaceuticals Corporation | $85.23 | 2024 | |
| Horizon Therapeutics Plc | $65.33 | 2023 | Krystexxa |
| Akebia Therapeutics INC | $62.80 | 2022-2024 | Vafseo |
| Glaxosmithkline, LLC. | $54.76 | 2023-2024 | Benlysta, Jesduvroq |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $52.25 | 2024 | |
| Kyowa Kirin, INC. | $26.95 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $23.44 | 2024 | Crysvita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.07 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Ramesh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.